Elekta stock holds steady as turnaround story and margins stay in focus

Elekta stock (ISIN SE0000163628) remains closely watched by investors as the Swedish radiotherapy specialist continues its operational turnaround, with recent results highlighting improving margins and solid demand for its treatment systems as of September 18, 2026. According to Morningstar, Elekta is in the midst of a multi-year turnaround that aims to improve profitability while benefiting from industrywide growth in cancer treatment demand.

Margins and revenue trends underpin the Elekta stock story

Elekta AB, the Stockholm-listed oncology technology company, has most recently reported results that show revenue growth and margin improvements versus the prior year, with the latest available figures covering its most recent fiscal period within the last two years. According to Morningstar on September 18, 2026, Elekta is working through a turnaround that includes efforts to lift operating margins from previously subdued levels, with recent reported figures showing progress compared with earlier years. While the exact quarterly numbers are not detailed in that overview, the assessment points to ongoing improvements in profitability metrics as the company executes on its strategy.

The company’s business model is built around radiotherapy and radiosurgery equipment, treatment planning software and related services. A description of Elekta from Multiples.vc notes that Elekta develops, manufactures and distributes treatment planning systems for neurosurgery and radiotherapy, including stereotactic radiosurgery and brachytherapy, and that it has an installed base of more than 7,300 linear accelerators, Gamma Knife and Unity platforms as well as brachytherapy installations. This large installed base is a key driver of recurring service and software revenue, supporting the turnaround narrative and offering investors visibility into longer term cash flows.

Turnaround focus and analyst perspective on Elekta stock

The turnaround theme for Elekta stock is reinforced by the view that the company stands to benefit from industrywide tailwinds in oncology while needing to resolve past execution issues. According to Morningstar, Elekta’s recent performance has been challenging, but the shares are still considered attractive based on the longer term growth opportunity and the potential for further margin improvement. For investors, the key focus is whether the company can continue to expand operating margins while maintaining revenue growth from new system installations and upgrades to its installed base.

On the operational side, Elekta’s installed base of more than 7,300 treatment platforms, as highlighted by Multiples.vc, provides a natural opportunity for service contracts, software upgrades and replacement cycles. Compared with smaller peers with fewer installed systems, this scale can translate into more stable revenue streams, particularly in maintenance and support, which tends to carry higher margin than initial hardware sales. The turnaround therefore relies not only on new orders, but also on maximizing profitability from existing customers.

Elekta stock price context and investor takeaway

On its primary listing at Nasdaq Stockholm, Elekta stock is trading in Swedish krona, with the most recent available quotations as of mid September 2026 reflecting a relatively stable share price compared with prior weeks, although exact intraday figures and a specific closing price for September 18, 2026 are not detailed in the available sources. In this environment, investors often look at valuation in relation to Elekta’s installed base and its margin trajectory rather than short term price moves alone. The improving profitability picture described by Morningstar suggests that the stock’s risk-reward profile is closely tied to management’s ability to sustain margin expansion and convert industry growth into higher earnings.

More news and analyses on Elekta stock